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A promising strategy to improve the therapeutic eﬃciency of antimicrobial agents is targeted therapy. Although vancomycin has
been considered a gold standard for the therapy of MRSA pneumonia, clinical failure rates have also been reported owing to its
slow, time-dependent bactericidal activity, variable lung tissue penetration and poor intracellular penetration into macrophages.
Liposomal encapsulation has been established as an alternative for antimicrobial delivery to infected tissue macrophages and
oﬀers enhanced pharmacodynamics, pharmacokinetics and decreased toxicity compared to standard preparations. The aim of
the present work is to prepare vancomycin in two diﬀerent liposomal formulations, conventional and PEGylated liposomes using
diﬀerent methods. The prepared formulations were optimized for their particle size, encapsulation eﬃciency and physical stability.
The dehydration-rehydration was found to be the best preparation method. Both the conventional and PEGylated liposomal
formulations were successfully formulated with a narrow particle size and size distribution and % encapsulation eﬃciency of 9±2
and 12 ± 3, respectively. Both the formulations were stable at 4◦C for 3 months. These formulations were successfully used to
evaluate for their intracellular killing of MRSA and in vivo pharmacokinetic and bio-distribution studies.
1.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) has be-
come an increasingly important etiology of pneumonia both
in healthcare and community settings. Although previously
considered as a nosocomial pathogen, in recent years it
has been diagnosed with increased incidence at hospital
admission [1]. S. aureus causes a wide spectrum of mild to
severe infections both in humans and animals [2]. Several
factors contribute to the persistence and recurrence of these
infections, but an important feature is the ability of the
bacteria to invade and survive inside the phagocytic cells [3].
Vancomycin (Figure 1) has been considered a gold standard
for the therapy of MRSA infections yet is poorly con-
centrated within human macrophages [4, 5]. Vancomycin
is a branched, tricyclic, glycosylated, and nonribosomal
peptide produced by Streptomyces orientalis [6]. It produces
antibacterial activity without requiring the penetration of
the lipid membrane [7]. Vancomycin binds with high-
aﬃnity D-alanine-D-alanine C-terminus of late peptido-
glycan precursors to prevent transpeptidation required for
synthesis of bacterial cell walls [8]. Clinical failures with van-
comycin against methicillin-resistant Staphylococcus aureus
(MRSA) infections have challenged its standing as a ﬁrst-
line antimicrobial [9]. The use of antibiotic delivery systems
with capacity for selective distribution in phagocytic cells
is an important resource in improving antibiotic therapy
against intracellular infections. Liposomes have been widely
considered as potential drug delivery systems ever since the
publishedobservationofBanghamandcoworkers[10].They
are currently used as unique drug carriers in several cosmetic
and pharmaceutical industries. Liposomes are colloidal
vesicles ranging from few nanometers to several micrometers
in diameter with one or several lipid bilayers surrounding an
inner aqueous compartment [11, 12]. Liposomes are bio-
degradable, biocompatible, nontoxic, and nonimmunogenic2 ISRN Pharmaceutics
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Figure 1: Chemical structures of vancomycin (R = CH3) and norvancomycin (R = H).
[13]. They can entrap a wide variety of therapeutic drugs
including antimicrobial, and anticancer drugs [14]. Hydro-
philic drugs can be encapsulated in the aqueous core, and
lipophilic drugs can be entrapped in the lipid bilayers [13].
Several factors such as aqueous volume, membrane rigidity,
surface area, and preparation methods of liposomes have
inﬂuence on the encapsulation eﬃciency of liposomes [15,
16].
When conventional liposomes are administered in vivo,
they are rapidly cleared from the blood circulation by mon-
ocytes and macrophages and are thus accumulated in the
organs of reticuloendothelial system (RES), especially the
liver and spleen [17, 18], which makes them to be a more
relevant target for intracellular infections localized in these
tissues [19]. Unlike conventional liposomes, PEGylated li-
posomes are able to avoid rapid hepatosplenic uptake.
Owing to the biocompatible PEG coating on their surface,
PEGylated liposomes delay opsonization and hence allow
for relatively longer blood circulation times, thus creating
possibilities to target intercellular pathogens and infected
macrophages outside the liver and spleen [20]. PEGylated
liposomes after long-term circulation in blood extravasate
in the infected tissues and eventually end up in deep-seated
tissue macrophages, thus acting as site-speciﬁc drug delivery
systems [14].
Vancomycin, being highly hydrophilic in nature, is not
an ideal candidate drug for liposome encapsulation. In the
present work, several methods have been attempted for this
challenging endeavor. In general, entrapment of hydrophilic
drugsusingthepassiveloadingﬁlmhydrationmethod[10]is
noteﬃcient.ThepHgradientmethodleadingtoquantitative
drug loading of vesicles through inward active drug diﬀusion
is limited to drugs of small molecular weight and certain
structural characteristics such as charge property [21]. On
the other hand, the dehydration-rehydration vesicle (DRV)
method [15] can entrap drugs regardless of their molecular
size, but the size of liposomes is relatively large. However,
smaller-sized liposomes entrapping vancomycin with high
eﬃciency can be prepared using a modiﬁed dehydration-
rehydration method [22, 23]. In the modiﬁed DRV method,
preformed empty small unilamellar liposomes are subjected
to dehydration in the presence of appropriate ratio of sugar
to lipid, and then the drug destined to entrapment is added
to empty liposomes in solution form, resulting in increased
entrapment compared to other conventional methods.
In this study, our goal was to develop novel vancomycin
liposomal formulations and characterize their stability pro-
ﬁles.
2.MaterialsandMethods
2.1. Materials. For the preparation of liposomal formula-
t i o n ,1 ,2 - d i s t e a r o y l - sn-glycero-3-phosphocholine (DSPC)
and MPEG-2000-DSPE [N-(Carbonyl-methoxypolyethyl-
eneglycol 2000)-1,2 distearoyl-sn-glycero-3-phosphoetha-
nolamine] were obtained from Genzyme Pharmaceuticals
(Cambridge, MA). Cholesterol, vancomycin hydrochloride,
sodium chloride, sucrose, and triﬂuoroacetic acid wereISRN Pharmaceutics 3
obtained from Sigma Chemicals (St. Louis, MO). Norvan-
comycin (Figure 1) was obtained from Northern China
Pharmaceutical Corporation (Shijiazhuang, Hebei, China).
Potassium chloride and dibasic sodium phosphate were ob-
tained from Baker (Philipsburg, NJ). Monobasic potassium
phosphate was procured from Fisher Scientiﬁc (Houston,
TX). HPLC-grade chloroform, acetonitrile, and methanol
were obtained from EMD Chemicals (Gibbstown, NJ).
Nanopure water was used for all experiments.
2.2. Preparation of Vancomycin Liposomes. The liposomes
were initially prepared using the thin-ﬁlm hydration method
[10] and the ammonium sulfate gradient method [23],
reported elsewhere. Using thin-ﬁlm hydration method,
brieﬂy, required amounts of lipids and cholesterol were
dissolved in chloroform, and a thin ﬁlm was formed on the
inner side of the round bottom ﬂask, by evaporating the
solvent under vacuum using a rotavapor. The lipid ﬁlm
formed was stored overnight in vacuum desiccator to elim-
inate traces of chloroform. The ﬁlm was then hydrated at
58◦C, above the Tc of DSPC, using 10mL of PBS (pH-
7.0) containing 50mg of vancomycin. The formed liposomes
were then sonicated using a probe sonicator in 5 cycles of
2min each and were then serially sized by extrusion through
0.8, 0.4, and 0.2µm pore-sized polycarbonate membranes.
The un-encapsulated drug was then separated using se-
pharose-4B column and the encapsulation eﬃciency was
calculated spectrophotometrically at 280nm. The liposo-
mal fractions collected from the sepharose column were
pooled and lyophilized after addition of suitable amount of
sucrose.
D u et op o o re n c a p s u l a t i o ne ﬃciency of vancomycin us-
ing the thin-ﬁlm hydration method, the liposomes were
then prepared using a modiﬁed pH gradient method. Brieﬂy
the lipids were dissolved in a round-bottomed ﬂask using
chloroform, which was then removed by means of a rotary
evaporator and by an overnight storage in a desiccator, thus
allowing the formation of a thin lipid ﬁlm. The lipid ﬁlm
was then hydrated with 1mL of 250mM ammonium sulfate
solutionandthensubjectedto5cyclesoffreezing(at −80◦C)
and thawing (with a water bath at 40◦C), thus achieving a
pH gradient with a homogenous acid environment in the
intraliposomal aqueous compartments. Multilamellar vesi-
cles were then subjected to extrusion through 0.8, 0.4, and
0.2µm pore-sized polycarbonate membranes. Unentrapped
ammonium sulfate solution was removed by centrifugation
at 4000rpm for 15min. The small unilamellar vesicles
obtained after centrifugation were suspended in 5mL of
drug solution (50mg/5mL), and the resulting solution was
allowed to equilibrate at room temperature for 3 hours. The
unentrapped vancomycin was removed using a sepharose-
4B column. The liposomes were passed through 100mL of
sepharose 4B column, and diﬀerent fractions were collected
and the liposomal fractions were pooled. The particle size
and encapsulation eﬃciency of the prepared liposomal for-
mulations were determined. The pooled liposomal fractions
were subjected to lyophilization by adding suitable amount
of sucrose as the cryoprotectant.
Due to poor encapsulation eﬃciency and poor stability
of the prepared formulations using the above methods,
it was decided to prepare subsequent formulations using
a modiﬁed dehydration-rehydration method [24]. Both the
conventional and PEGylated vancomycin liposomal formu-
lations were prepared using the lipids DSPC, cholesterol,
andMPEG-2000-DSPEin3:1:0and3:1:0.02molarratios,
respectively. The lipids were dissolved in 7mL of chloroform
and rotary-evaporated in a round-bottomed ﬂask under
vacuum, thus allowing the formation of a thin layer of
lipid ﬁlm. The lipid ﬁlm formed was stored overnight in
vacuum desiccator to eliminate trace of chloroform. The
lipid ﬁlm was then hydrated at 58◦C, above the Tc of DSPC
with 5mL of nanopure water for 30min to yield MLV
liposomes. The MLVs thus formed were then sonicated for
2min using a probe sonicator. The lipid dispersion was
t h e nf r o z e na t−80◦C and lyophilized overnight with the
addition of sucrose to stabilize the liposomes during freeze-
drying. DRVs were prepared by adding 1mL of concentrated
solution of vancomycin (50mg/mL in PBS, pH 7.0) to the
lyophilized liposomes and vortexing. The gel produced was
allowed to stay at room temperature for 30min and then
diluted with 4mL of PBS. The DRVs were then serially sized
by extrusion through 0.8, 0.4, and 0.2µm pore-sized poly-
carbonate membranes. During the extrusion, the tempera-
ture of the extruder was maintained above 60◦C using hot
water circulation. Vancomycin-containing liposomes were
separated from nonentrapped vancomycin by ultracentrifu-
gation at 30,000rpm (105,000×g) for 30min, and the
liposomalpelletobtainedwaswashedoncewith1mLofPBS.
TheﬁnalpelletwasresuspendedinPBS,andthepreparations
were stored at 4◦C.
2.3. Characterization of Liposomes
2.3.1. Particle Size Measurement. T h ep a r t i c l es i z eo ft h el i -
posomes was measured using a Nicomp submicron particle
sizer (Model 370, Santa Barbara, California). Ten µLo fl i po s -
omal suspension was taken and suitably diluted to measure
the mean diameter of DRVs. Gaussian distribution was used
as the standard to measure the particle size.
2.3.2. Determination of Encapsulation Eﬃciency (% EE). En-
capsulation eﬃciency was determined as the percentage of
vancomycin incorporated into DRVs relative to the initial
amount of drug added. The lipid vesicles were lysed using
10% Triton X-100 to determine the amount of drug present.
Brieﬂy, 25µL of liposomal suspension was added to 975µL
of 10% Triton X-100 and vortexed for 5min to facilitate lysis
of the DRVs. The supernatant (100µL) was taken and used
for HPLC analysis by addition of 5µL of norvancomycin
(100µg/mL) as the internal standard. Encapsulation eﬃ-
ciency was calculated using:
% Encapsulation eﬃciency =
ADRVs
Asol
×100, (1)
whereADRVs is the amount of drug present in liposomes after
lysis with 10% Triton X-100 and Asol is the amount of drug
added initially.4 ISRN Pharmaceutics
Table 1: Particle size and encapsulation eﬃciency of conventional
and PEGylated liposomes prepared using the DRV method.
Formulation Size (nm) % EE Concentration
(mg/mL)
Conventional liposomes 254±147 9.0 ±2.21 . 1 3
PEGylated liposomes 245±139 12.6±3.01 . 5 8
2.4. HPLC Method Development for the Quantiﬁcation of
Vancomycin Released from Liposomes. A sensitive, rapid, and
accurate high-performance liquid chromatography method
to measure the amount of vancomycin incorporated into
DRVs was developed and validated. The details will be
reported in a separate publication.
2.5. Characterization of Physical Stability of Liposomes. The
particle size, size distribution, change in mean particle size
with time, and physical appearance of the liposomal suspen-
sion are sensible indicators of the kinetic stability of liposo-
mal suspensions. The particle size and the size distribution
of both the conventional and PEGylated liposomes were
measured, and 5mL each of both the formulations was
stored at 4◦C, room temperature (24◦C), and physiologic
temperature (37◦C). At speciﬁc time intervals of 1, 2, and
3 months, the samples were taken, and their physical ap-
pearance was examined. In addition, the mean particle
size, size distribution, and encapsulation eﬃciency of both
formulations were measured as described above.
3. Results
3.1. Formulation and Characterization of Liposomes
3.1.1. Particle Size. Both the conventional and PEGylated li-
posomal formulations prepared by thin-ﬁlm hydration have
shown a mean particle size of 228 ± 150nm and 103 ±
45nm, respectively, and those prepared by ammonium
sulfate gradient method have shown a mean particle size of
242 ±87nm and 229 ±66nm, respectively.
The mean particle size of conventional liposomes pre-
pared by dehydration-rehydration method was 254±147nm
andthatofPEGylatedliposomes was245±139nm (Table 1).
PEGylated liposomes even without extrusion through differ-
ent-sized ﬁlters had lower particle size compared to conven-
tional liposomes. The size distribution curve was uniform
for both the formulations. Low standard deviation for PEGy-
lated formulations showed narrow distribution compared to
conventional liposomes.
3.1.2. Encapsulation Eﬃciency. Encapsulation eﬃciency, de-
termined as the percentage of vancomycin incorporated into
DRVs relative to the initial amount of drug added, was
initially calculated spectrophotometrically at 280nm, when
the liposomes were prepared by thin-ﬁlm hydration and am-
monium sulfate gradient methods. The %EE of conventional
liposomes prepared by thin-ﬁlm hydration was 2 ± 1%
and that of PEGylated formulation was 4 ± 2%, whereas
the conventional and PEGylated liposomes prepared by
ammonium sulfate gradient method showed a %EE of 0.3
and 0.1%, respectively. When the liposomes were prepared
by dehydration-rehydration method the %EE was calculated
using HPLC after lysing the liposomes in 10% triton X-
100. The encapsulation eﬃciency of conventional liposomes
was 9 ± 2% and that of PEGylated liposomes was 13 ± 3%
(Table 1). There was considerable improvement in encapsu-
lation eﬃciency when DRV method was used for liposomal
preparation compared to those prepared by thin-ﬁlm hydra-
tion and ammonium sulfate gradient methods.
3.2. Physical Stability of Liposomes. The physical appearance
of both the conventional and PEGylated liposomal formula-
tions stored at 4◦C, 24◦C, and 37◦C for 1, 2, and 3 months
was evaluated. At the end of 1 month, all the liposomal
formulations stored at 4◦Ca n d2 4 ◦C were stable. But for
the formulations stored at 37◦C, a change in the color and
viscosity of the liposomal suspension was observed. Growth
of fungus on top of the suspension stored at 37◦Cw a s
observed with both conventional and PEGylated liposomal
formulations, which led to discontinuation of the stability
studies at 37◦C after 1 month. At the end of 2nd and 3rd
months, both the formulations stored at 24◦C showed fungal
growth, while those at 4◦C were stable.
The particle size distribution and the mean particle size
of both the formulations as a function of temperature were
also evaluated after the end of 1, 2, and 3 months. Except for
the liposomes stored at 37◦C, there is no signiﬁcant change
in the particle size and size distribution of other liposomal
formulations stored at 4◦Ca n d2 4 ◦C( Table 2).
Encapsulation eﬃciency of the conventional liposomes
stored at 4◦C decreased by 6, 32, and 34%, whereas those
stored at 24◦C decreased by 30, 60, and 70% at the end of
1, 2 and 3 months respectively. For the PEGylated liposomes
stored at 4◦C, encapsulation eﬃciency decreased by 13, 19,
and 23%, whereas for those stored at 24◦C decreased by 27,
59, and 61% at the end of 1, 2, and 3 months, respectively.
The results of particle size and % EE of both the formulation
over the span of 3 months were shown in Figure 2.
4. Discussion
MRSAhasbecomeanimportantetiologyofpneumoniaboth
in healthcare and community settings [1]. Although consid-
ered to be an extracellular pathogen, Staphylococcus aureus
is able to invade a variety of mammalian, nonprofessional
phagocytes and can also survive engulfment by professional
phagocytes such as monocytes and neutrophils [25, 26].
Thus antibiotics which penetrate these cellshave been shown
to have superior clinical eﬃcacy. Vancomycin has been
the cornerstone of therapy for serious MRSA-associated
infections. However, vancomycin has been associated with
clinical failure rates [27, 28], due to poor penetration into
eukaryotic cells, which is mainly essential for eradication of
intracellular bacteria. Furthermore, vancomycin tolerance is
emerging as evidenced by reports of incremental increases
in MIC (“MIC creep”) in MRSA isolates [29, 30]. Invasive
infections due to MRSA strains with MICs ranging fromISRN Pharmaceutics 5
Table 2: Stability of conventional and PEGylated vancomycin liposomes at the end of 1, 2 and 3 months.
Formulation Test condition Temp % EE Particle size (nm) Physical appearance
Conventional
liposomes
0 Mon 12.40 234 ±92 Milky suspension
1M o n
4◦C 11.71 258 ±111 Milky suspension
24◦C 8.68 242 ±97 Milky suspension; slight coagulation
37◦C 4.28 605 ±800 Slightly dark color and thicker suspension, with growth of
fungus on top, dispersed upon shaking.
2M o n
4◦C 8.47 260 ±85 Milky suspension
24◦C 5.01 305 ±112 Slight dark color suspension with formation of big clumps
of fungus, which are not dispersible upon shaking.
3M o n
4◦C 8.23 250 ±97 Milky suspension
24◦C 3.67 356 ±43 Slight dark color suspension with formation of big clumps
of fungus, which are not dispersible upon shaking
PEGylated liposomes
0 Mon 12.78 181 ±82 Milky suspension
1M o n
4◦C 11.17 202 ±107 Milky suspension
24◦C 9.40 200 ±106 Milky suspension; slight coagulation
37◦C 6.90 208 ±109 Slightly dark color and thicker suspension, with growth of
fungus on top, dispersed upon shaking.
2M o n
4◦C 10.33 205 ±93 Milky suspension
24◦C 5.29 355 ±154 Slight dark color suspension with formation of big clumps
of fungus, which are not dispersible upon shaking.
3M o n
4◦C 9.89 210 ±88 Milky suspension
24◦C 4.98 290 ±120 Slight dark color suspension with formation of big clumps
of fungus, which are not dispersible upon shaking
1t o2 µg/mL have lower success rates as compared to
infections due to strains with MIC ≤ 0.5µg/mL [31, 32].
Pharmacodynamic studies suggest that curative vancomycin
treatment of MRSA infection requires achieving a ratio of
the area under the concentration time curve for 24h to
minimum inhibitory concentration (AUC24/MIC) ≥ 400
[33]. Higher serum vancomycin levels would therefore be
needed and in turn would increase the risk of nephrotoxicity
[34]. Liposomal encapsulation of certain drugs has been
shown to deliver the entrapped drug into phagocytic cells
leading to intracellular drug accumulation [13, 35]. We
sought to construct liposomes with high yield entrapment
of vancomycin as well as favorable stability, which allow
potentially nephrotoxic vancomycin to be delivered in high
enough concentrations in the lung to eﬀectively kill viable
tissue-invasive MRSA pathogens while sparing the host of
worsening injury to the kidneys.
Both the conventional and PEGylated liposomal formu-
lationswereinitiallypreparedbythin-ﬁlmhydrationmethod
[10] and ammonium sulfate gradient method [23]. High
entrapment of vancomycin using passive loading methods
was not enough. The active entrapment method using a
transmembrane pH gradient failed to entrap vancomycin
properly because of its large molecular size and charge
property. The encapsulation eﬃciency was very low for both
the formulations, especially for PEGylated liposomes, the
encapsulation was around 5%. A change in amount of van-
comycin to be encapsulated from 50mg to 100mg did not
cause any appreciable change in the ﬁnal encapsulation
eﬃciency. To further improve the encapsulation eﬃciency
of vancomycin, a modiﬁed dehydration-rehydration method
[24] was used. In this method, a suspension of empty
liposomes is lyophilized. Since such lipid has a highly
organizedstructure,additionofwaterwiththedesiredsolute
can rehydrate, fuse, and reseal vesicles with high capture
eﬃciency, unlike the conventional methods. As vancomycin
is highly water soluble, its encapsulation is commonly
correlated with the concentration of encapsulated aqueous
volume. DRVs are liposomes that are formulated under mild
conditions and have the capability to entrap substantially
high amounts of hydrophilic solutes, compared to other
types of liposomes [15]. Their high entrapment is due
to the fact that preformed empty liposomes are disrupted
during a freeze-drying cycle and subsequently rehydrated
in the presence of a concentrated solution of the solute to
be encapsulated. DSPC was used as the phospholipid for
preparation of both the liposomal formulations. As DSPC
has high transition temperature of 56◦C, it is quite stable and
is in solid state holding the drug and decreasing its release
rate. Incorporation of cholesterol protects the DRVs from
osmotic shock [15]. Large unilamellar liposomes (LUVs)
are particularly useful for passive targeting to macrophages.
LUVs are taken up by phagocytic cells more rapidly than
SUVs.LUVsprovideasystemthatallowsrelativelyhightrap-
ping eﬃciency as well as relatively slow clearance. LUVs of
reproduciblesizeandhomogeneitywerepreparedbysequen-
tial extrusion of multilamellar liposomes through polycar-
bonate membranes with no degradation of phospholipids.
It has been well documented for various liposomal drug
formulations that the liposomes without sugar were signif-
icantly larger than those prepared with sugar [22, 36]. The
ability of sugars to prevent vesicle fusion has been attributed6 ISRN Pharmaceutics
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Figure 2: Physical stability of conventional (a) and PEGylated (b)
liposomalformulationsofvancomycinat4◦Cbytheendof1,2,and
3m o n t h s .
to the formation of a stable glassy state as well as direct
interaction between the polar head groups of phospholipids
and sugars [37, 38]. Diﬀerent types of cryoprotectants like
sucrose, lactose, mannitol, and trehalose were investigated.
The particle size of the liposomes appeared to be stable
in the ﬁnal liposomal formulations when sucrose was used
as the cryoprotectant. Presence of sucrose preserved the
stability of the vesicles during freeze-drying and also allowed
for vesicle destabilization during rehydration, so that more
vancomycin could be entrapped into the aqueous phase.
However, higher initial concentrations of sucrose caused
a decrease in the vancomycin entrapment. PEGylation of
liposomes signiﬁcantly reduces RES uptake and prolongs the
blood circulation time [39], which mainly depends on both
the amount of grafted PEG and the molecular weight of the
polymer.AdecreaseintheamountofMPEG-DSPEfrom6to
4mg caused an increase in the encapsulation eﬃciency. For
the separation of nonencapsulated drug from encapsulated
drug, centrifree ﬁltration and gel ﬁltration (using sepharose-
4B) techniques were used initially [40]. The upper limit
for lipid concentration was 5mg/mL using the centrifree
method, and separation using gel chromatography led to the
dilution of the liposomal preparation. These drawbacks led
to the use of ultracentrifugation technique for the separation
ofunencapsulateddrug.Theobtainedliposomalpreparation
waslysedusingtritonX-100andencapsulationeﬃciencywas
accuratelydeterminedbytheHPLCmethod.Alltheprepared
formulations were stored as suspensions, as lyophilizing the
liposomes for the second time during the preparation did
not yield a satisfactory cake. The liposomal suspensions
were stable and could be able to retain the encapsulated
vancomycin when stored at 4◦C, which is evident from the
stability experimental results.
Both the liposomal formulations prepared by the DRV
method had a very narrow particle size distribution. The size
of liposomes is an important determinant of encapsulation
eﬃciency. As the size of liposomes increases, the entrapped
volume increases for constant lamellarity [41]. However,
larger liposomes have short circulation half-life as they are
rapidly eliminated from the circulation by the RES [42].
PEG lipids reduce the requirement of small size for long
circulation, but their inﬂuence is restricted within a size
range. A size range of 210–275nm is the optimum size
where PEG liposomes retain their prolonged circulation
[43]. Therefore a balance between the liposomal size and
entrapment eﬃciency was maintained in case of both the
conventional and PEGylated vancomycin liposomal formu-
lations.
The stability of liposomes is another important factor
to be considered in the development of an eﬃcient drug
delivery system. Therefore, we evaluated the stability of both
the liposomal formulations at diﬀerent temperatures, to
mimic physiological conditions. The results obtained have
shown that the prepared vesicles were physically and chem-
ically stable at 4◦C for 3 months. No signiﬁcant change in
the physical appearance, particle size, and size distribution
was observed for both the formulations during the course of
stability study at 4◦C. But the formulations stored at 24◦C
and 37◦C showed a slight increase in particle size, which may
be due to the aggregation or swelling of liposomes. Slight
decrease in the encapsulation eﬃciency was observed which
shows a signiﬁcant leakage of vancomycin from both the
formulations over time.
Both conventional and PEGylated liposomal vancomycin
formulations prepared by the DRV method described in
this paper and stored at 4◦C have been used successfully
in an in vivo study to investigate the pharmacokinetics
and biodistribution of vancomycin in various formulations.
It has been demonstrated that both conventional and
PEGylated liposomal formulations of vancomycin lead to
enhanced biodistribution in vivo compared to standard van-
comycin. Furthermore, PEGylated liposomal vancomycin
shows improved pharmacokinetics and prolonged half-life
compared to conventional liposomal formulation.
5. Conclusions
Both the conventional and PEGylated liposomal formu-
lations of vancomycin were successfully prepared usingISRN Pharmaceutics 7
a modiﬁed dehydration-rehydration method. The DRV
method uses mild conditions and has the capability to
entrap substantially high amounts of hydrophilic solutes,
compared to other types. Both the formulations have a nar-
row particle size and size distribution and % encapsulation
eﬃciencyof9±2and12±3,respectively.Additionofsucrose
preserved the stability of the formulations during freeze-
drying. The prepared formulations were stable in suspension
form at 4◦C for 3 months.
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